Dr Antonio Passaro speaks to ecancer at the European Lung Cancer Congress 2019.
He outlines the Phase III trial which evaluates the role of afatinib in patients with EGFR NSCLC.
Dr Passaro describes the data so far, and also some of the future prospects for the research, including a comparison of clinical trail and clinical practise data.
He finishes by outlining the toxicity profile of the combination.